Cargando…

Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus

Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Takashi, Shirai, Kohji, Nagayama, Daiji, Nakamura, Shoko, Oka, Rena, Tanaka, Sho, Watanabe, Yasuhiro, Imamura, Haruki, Sato, Yuta, Kawana, Hidetoshi, Ohira, Masahiro, Saiki, Atsuhito, Shimizu, Naomi, Tatsuno, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629745/
https://www.ncbi.nlm.nih.gov/pubmed/30584220
http://dx.doi.org/10.5551/jat.45799
_version_ 1783435154490916864
author Yamaguchi, Takashi
Shirai, Kohji
Nagayama, Daiji
Nakamura, Shoko
Oka, Rena
Tanaka, Sho
Watanabe, Yasuhiro
Imamura, Haruki
Sato, Yuta
Kawana, Hidetoshi
Ohira, Masahiro
Saiki, Atsuhito
Shimizu, Naomi
Tatsuno, Ichiro
author_facet Yamaguchi, Takashi
Shirai, Kohji
Nagayama, Daiji
Nakamura, Shoko
Oka, Rena
Tanaka, Sho
Watanabe, Yasuhiro
Imamura, Haruki
Sato, Yuta
Kawana, Hidetoshi
Ohira, Masahiro
Saiki, Atsuhito
Shimizu, Naomi
Tatsuno, Ichiro
author_sort Yamaguchi, Takashi
collection PubMed
description Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress. Methods: A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period. Results: Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease. Conclusion: Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes.
format Online
Article
Text
id pubmed-6629745
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-66297452019-07-23 Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus Yamaguchi, Takashi Shirai, Kohji Nagayama, Daiji Nakamura, Shoko Oka, Rena Tanaka, Sho Watanabe, Yasuhiro Imamura, Haruki Sato, Yuta Kawana, Hidetoshi Ohira, Masahiro Saiki, Atsuhito Shimizu, Naomi Tatsuno, Ichiro J Atheroscler Thromb Original Article Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress. Methods: A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period. Results: Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease. Conclusion: Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. Japan Atherosclerosis Society 2019-07-01 /pmc/articles/PMC6629745/ /pubmed/30584220 http://dx.doi.org/10.5551/jat.45799 Text en 2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Yamaguchi, Takashi
Shirai, Kohji
Nagayama, Daiji
Nakamura, Shoko
Oka, Rena
Tanaka, Sho
Watanabe, Yasuhiro
Imamura, Haruki
Sato, Yuta
Kawana, Hidetoshi
Ohira, Masahiro
Saiki, Atsuhito
Shimizu, Naomi
Tatsuno, Ichiro
Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title_full Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title_fullStr Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title_full_unstemmed Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title_short Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
title_sort bezafibrate ameliorates arterial stiffness assessed by cardio-ankle vascular index in hypertriglyceridemic patients with type 2 diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629745/
https://www.ncbi.nlm.nih.gov/pubmed/30584220
http://dx.doi.org/10.5551/jat.45799
work_keys_str_mv AT yamaguchitakashi bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT shiraikohji bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT nagayamadaiji bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT nakamurashoko bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT okarena bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT tanakasho bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT watanabeyasuhiro bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT imamuraharuki bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT satoyuta bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT kawanahidetoshi bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT ohiramasahiro bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT saikiatsuhito bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT shimizunaomi bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus
AT tatsunoichiro bezafibrateamelioratesarterialstiffnessassessedbycardioanklevascularindexinhypertriglyceridemicpatientswithtype2diabetesmellitus